These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 11328410

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
    Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM.
    Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
    [Abstract] [Full Text] [Related]

  • 5. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B.
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A.
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [Abstract] [Full Text] [Related]

  • 11. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
    Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, Cha SS, Strickler JG.
    Cancer; 1994 Mar 01; 73(5):1460-6. PubMed ID: 7906608
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.
    Nazeer T, Ballouk F, Malfetano JH, Figge H, Ambros RA.
    Am J Obstet Gynecol; 1995 Dec 01; 173(6):1829-34. PubMed ID: 8610771
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
    Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F, Müller V.
    Int J Biol Markers; 2006 Dec 01; 21(3):131-40. PubMed ID: 17013794
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.